Myriad Genetics and Intermountain Precision Genomics are now certified to offer solid tumor testing to patients in all 50 U.S. states after receiving the New York State Clinical Laboratory Permit. This achievement follows a recent site inspection as part of the New York State Department of Health Clinical Laboratory Evaluation Program. "The NYS certification represents an important step forward in the advancement of precision medicine by increasing access to genetic testing that can help patients with cancer and their providers determine more targeted treatment decisions," said Michael Lyons, president of Oncology, Myriad Genetics. "Working in close collaboration with Intermountain Precision Genomics, we’re now able to offer the complete Precise(TM) Oncology Solutions suite in all 50 states." Myriad’s Precise Tumor test, also offered by Intermountain Precision Genomics as TheraMap: Solid Tumor, analyzes a patient’s tumor DNA to discover what changes, or gene mutations, are causing the cancer. Specialists apply the results to recommend a targeted treatment plan for the patient’s unique tumor profile.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- 77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
- Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
- Myriad Genetics, SimonMed Imaging collaborate to advance precision medicine
- Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
- Myriad Genetics price target raised to $24 from $17 at Stephens